abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
EBITDA Growth
133.80%
TTM · Period ending:
HQL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported133.80%period ending
Latest reported133.80%period ending
HQL TTM EBITDA YoY % (-63.68% → 133.80%)
Year-over-year change
High-resolution chart · PNG
HQL ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 133.7952% | |
| 77.1332% | |
| 25.3103% | |
| 212.6666% | |
| 196.1261% | |
| -239.3896% | |
| -175.1031% | |
| -116.9981% | |
| -44.2037% | |
| 54.8539% | |
| 417.8886% | |
| 100% | |
| 100% | |
| 0% | |
| 0% | |
| 0% | |
| 50% | |
| -100% | |
| -100.0027% | |
| -99.7456% | |
| -99.9062% | |
| -75.7187% | |
| -32.1316% | |
| -0.1806% | |
| 144.1954% | |
| 257.7291% | |
| 576.9886% | |
| -14.7178% | |
| -87.6708% | |
| -61.7896% | |
| -48.4471% | |
| 4.9584% | |
| 125.2593% | |
| 72.7292% | |
| 13.2427% | |
| -2.8844% | |
| -16.3713% | |
| -2.4156% | |
| 13.412% | |
| 19.321% | |
| 26.8144% | |
| 158.7863% | |
| 909.417% | |
| 488.2209% | |
| -20.8672% | |
| -183.5897% | |
| -63.6757% |